WO2006106435A3 - Fusion protein comprising a hiv nef double mutant and its use therapy - Google Patents

Fusion protein comprising a hiv nef double mutant and its use therapy Download PDF

Info

Publication number
WO2006106435A3
WO2006106435A3 PCT/IB2006/001058 IB2006001058W WO2006106435A3 WO 2006106435 A3 WO2006106435 A3 WO 2006106435A3 IB 2006001058 W IB2006001058 W IB 2006001058W WO 2006106435 A3 WO2006106435 A3 WO 2006106435A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
double mutant
hiv nef
use therapy
nef
Prior art date
Application number
PCT/IB2006/001058
Other languages
French (fr)
Other versions
WO2006106435A2 (en
Inventor
Maurizio Federico
Original Assignee
Maurizio Federico
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maurizio Federico filed Critical Maurizio Federico
Priority to EP06744593A priority Critical patent/EP1976866A2/en
Publication of WO2006106435A2 publication Critical patent/WO2006106435A2/en
Publication of WO2006106435A3 publication Critical patent/WO2006106435A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C12N9/1211—Thymidine kinase (2.7.1.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Abstract

A fusion protein comprising a Nef double mutant (V 153 L, E 177 G) polypeptide (hereinafter Nef7) as shown in Seq ID No: 1 associated with a heterologous polypeptide.
PCT/IB2006/001058 2005-04-06 2006-04-05 Fusion protein comprising a hiv nef double mutant and its use therapy WO2006106435A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06744593A EP1976866A2 (en) 2005-04-06 2006-04-05 Fusion protein comprising a hiv nef double mutant and its use therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0507003.2 2005-04-06
GBGB0507003.2A GB0507003D0 (en) 2005-04-06 2005-04-06 Therapeutic

Publications (2)

Publication Number Publication Date
WO2006106435A2 WO2006106435A2 (en) 2006-10-12
WO2006106435A3 true WO2006106435A3 (en) 2007-04-05

Family

ID=34586809

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001058 WO2006106435A2 (en) 2005-04-06 2006-04-05 Fusion protein comprising a hiv nef double mutant and its use therapy

Country Status (3)

Country Link
EP (1) EP1976866A2 (en)
GB (1) GB0507003D0 (en)
WO (1) WO2006106435A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094994A2 (en) 2001-05-18 2002-11-28 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US20100260787A1 (en) * 2009-04-09 2010-10-14 Kiromic Inc. Human sperm fibrous sheath (FS) proteins: new target antigens for use in therapeutic cancer vaccines and diagnostic screening and Methods of Using Same
CN109893648A (en) * 2013-06-28 2019-06-18 奥克兰联合服务有限公司 Amino acid conjugate and peptide conjugate and conjugation methods
BR112017013574A2 (en) 2014-12-23 2018-03-06 Verdon Daniel amino acid and peptide conjugates and uses thereof
EA201891639A1 (en) 2016-02-26 2019-06-28 Окленд Юнисервисес Лимитед Amino Acid and Peptide Conjugates and Method of Conjugation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016884A1 (en) * 1997-09-26 1999-04-08 Smithkline Beecham Biologicals S.A. Fusion proteins comprising hiv-1 tat and/or nef proteins
US20040087537A1 (en) * 2002-09-19 2004-05-06 Molmed Spa Compositions comprising fusion polypeptides HIV-Nef and NGF, and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999016884A1 (en) * 1997-09-26 1999-04-08 Smithkline Beecham Biologicals S.A. Fusion proteins comprising hiv-1 tat and/or nef proteins
US20040087537A1 (en) * 2002-09-19 2004-05-06 Molmed Spa Compositions comprising fusion polypeptides HIV-Nef and NGF, and methods of using the same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D'ALOJA PAOLA ET AL: "Genetic and functional analysis of the human immunodeficiency virus (HIV) type 1-inhibiting F12-HIVnef allele", JOURNAL OF GENERAL VIROLOGY, vol. 82, no. 11, November 2001 (2001-11-01), pages 2735 - 2745, XP002411121, ISSN: 0022-1317 *
PERETTI ET AL: "Cell Death Induced by the Herpes Simplex Virus-1 Thymidine Kinase Delivered by Human Immunodeficiency Virus-1-Based Virus-like Particles", MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 12, no. 6, December 2005 (2005-12-01), pages 1185 - 1196, XP005176627, ISSN: 1525-0016 *

Also Published As

Publication number Publication date
WO2006106435A2 (en) 2006-10-12
EP1976866A2 (en) 2008-10-08
GB0507003D0 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
WO2004094466A3 (en) Recombinant influenza viruses holding a mutation in a transmembrane protein gene
HRP20090245T1 (en) Pyy agonists and uses thereof
WO2006112930A3 (en) Q3 sparc deletion mutant and uses thereof
MX353234B (en) Polypeptide variants with altered effector function.
WO2006106435A3 (en) Fusion protein comprising a hiv nef double mutant and its use therapy
WO2008031045A3 (en) Aquaretic and natriuretic polypeptides lacking vasodilatory activity
WO2004111217A3 (en) Variant pseudomonas polypeptides having a non-maltogenic exoamylase activity and their use in preparing food products
WO2006074440A3 (en) Fence system
EP2949658A3 (en) Peptides that specifically bind HGF receptor (cMet) and uses thereof
EP1824971A4 (en) Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
WO2006135793A3 (en) Protein engineering with analogous contact environments
WO2003072746A3 (en) Subtilisin carlsberg proteins with reduced immunogenicity
WO2002060978A1 (en) Branched polyalkylene glycols
WO2003089574A3 (en) Synthetic glyco-lipo-peptides as vaccines
WO2002044384A3 (en) T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
MXPA04002103A (en) A caspase- 8 binding protein, its preparation and use.
USD506647S1 (en) Knife
WO2006123157A3 (en) Nematistatic protein
WO2003014149A3 (en) Genetically modified cyclic-nucleotide controlled ion channels and the use thereof
WO2003020767A3 (en) Antibodies against caspase-8, their preparation and use
USD537720S1 (en) Bottle
WO2007073845A8 (en) Polypeptide having esterase activity and recombinant esterase and use thereof
WO2005057486A3 (en) Protein engineering with analogous contact environments
EP1720985A4 (en) Polypeptide participating in pyridoxine biosynthesis, a polynucleotide coding the polypeptide and those uses
USD526671S1 (en) Pivot unit for gripper systems

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWE Wipo information: entry into national phase

Ref document number: 2006744593

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06744593

Country of ref document: EP

Kind code of ref document: A2